- Home
- OSUR vs NTHI Comparison
OSUR vs NTHI Comparison
Compare OSUR & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSUR | NTHI |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.2M | 195.5M |
| IPO Year | 1986 | N/A |
Fundamental Metrics
Financial Performance| Metric | OSUR | NTHI |
|---|---|---|
| Price | $2.40 | $6.98 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 742.3K | 74.3K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $125,703,000.00 | $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.08 | $3.20 |
| 52 Week High | $4.22 | $25.00 |
Technical Indicators
Market Signals| Indicator | OSUR | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 37.62 |
| Support Level | $2.41 | $8.63 |
| Resistance Level | $2.53 | $10.44 |
| Average True Range (ATR) | 0.11 | 0.93 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 15.52 | 15.35 |
Price Performance
Historical ComparisonAbout OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).